Strides Pharma Science has fixed 09 September 2024 as record date for final dividend of Rs 2.50 per share. Powered by Capital Market - Live

The good manufacturing practices (GMP) inspection was conducted from 1 April to 5 April 2024. The USFDA has determined that the inspection classification of this facility is voluntary action indicated (VAI). Strides Alathur facility caters to the U.S. and other regulated markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets. Strides remains committed to the highest standards of compliance and will continue to focus on manufacturing high-quality pharmaceutical products for the Global markets, the company stated in exchange filing. Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. The company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24. Revenue from operations stood at Rs 1,087.50 crore in the quarter ended June 2024, registering a growth of 16.93% YoY. The scrip declined 1.27% to Rs 1,297 on the BSE. Powered by Capital Market - Live

Strides Alathur, a wholly owned subsidiary of Strides Pharma Science (Strides) has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations facility at Alathur, Chennai thereby successfully concluding the Good Manufacturing Practices (GMP) inspection conducted between April 1-5, 2024. USFDA has determined that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). Strides Alathur facility caters to the U.S. and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets.Powered by Capital Market - Live

Strides Pharma, as a part of Group entites optimization exercises has liquidated its US unit by the relevant regulatory authorities of New Jersey. Altima Innovations Inc. was a non-operative entity so, its turnover for FY 2024 was NIL. The net worth of the company for FY ended 31 March 2024 was $6,620 (equivalent to approximately Rs 551,909). Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. The company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24. Revenue from operations stood at Rs 1,087.50 crore in the quarter ended June 2024, registering a growth of 16.93% YoY. Shares of Strides Pharma Science hit 52-week high of Rs 1,298.50 in today's intraday session. Powered by Capital Market - Live

Strides Pharma Science announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 September 2024 .Powered by Capital Market - Live

Strides Arcolab International (SAIL UK), a wholly owned subsidiary of Strides Pharma Science in UK, proposes to acquire balance stake in Strides Global Consumer Healthcare (Consumer UK) from the existing Investor. Consumer UK is an IP holding entity and is into the business of sale and distribution of pharmaceutical and other over-the-counter consumer health care products, through its subsidiaries in US and India. SAIL UK is currently holding 19% stake in Consumer UK. As at 31 March 2024, carrying value of this investment in the books of SAIL UK is NIL. SAIL UK is acquiring the balance 81% stake from the existing Investor at GBP One. Strides Group has assessed the business opportunity and would like to strengthen its existing portfolio with the CHC Brands which have good recall value. Strides can leverage its relationship with wholesalers in the US and other geographies and advance this business in various territories like US, UK and MENA.Powered by Capital Market - Live